Skip to main content

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model


Medicis Pharmaceuticals Corporation



) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 2%. By the end of trading, Medicis Pharmaceuticals Corporation fell $1.32 (-3%) to $42.03 on heavy volume. Throughout the day, 17 million shares of Medicis Pharmaceuticals Corporation exchanged hands as compared to its average daily volume of 2.2 million shares. The stock ranged in price between $40-$43.39 after having opened the day at $42.87 as compared to the previous trading day's close of $43.35. Other companies within the Drugs industry that declined today were:




), down 21.4%,

SciClone Pharmaceuticals



), down 19.4%,

Palatin Technologies


TheStreet Recommends


), down 15.2%, and

Array BioPharma



), down 13.8%.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Medicis Pharmaceutical Corporation, a specialty pharmaceutical company, engages in the development and marketing of various products for the treatment of dermatological and aesthetic conditions in the United States and Canada. Medicis Pharmaceuticals Corporation has a market cap of $2.53 billion and is part of the health care sector. The company has a P/E ratio of 42.9, above the S&P 500 P/E ratio of 17.7. Shares are up 30.4% year to date as of the close of trading on Thursday. Currently there are two analysts that rate Medicis Pharmaceuticals Corporation a buy, no analysts rate it a sell, and 11 rate it a hold.

TheStreet Ratings rates Medicis Pharmaceuticals Corporation as a


. The company's strengths can be seen in multiple areas, such as its revenue growth, good cash flow from operations, largely solid financial position with reasonable debt levels by most measures, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the positive front,

NABI Biopharmaceuticals



), up 495.4%,

Cytori Therapeutics



), up 18.9%,




), up 18.8%, and

Isis Pharmaceuticals



), up 14.5%, were all gainers within the drugs industry with

Biogen Idec



) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF



) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech




FREE for a limited time only: Get TheStreet Ratings #1 Stock Report NOW!